Tag: early detection

BROSSARD, Quebec, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), announces that it intends to extend the exercise period of an aggregate of 650,000 stock warrants (each a “Warrant”) issued as part of a non-brokered private placement of units initially announced on March 22, 2024. The Warrants initial exercise period is set to expire on September 22, 2025.

BROSSARD, Quebec, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), announces that it intends to extend the exercise period of an aggregate of 1,414,286 stock warrants (each a “Warrant”) issued as part of a non-brokered private placement of units initially announced on February 27, 2024. The Warrants initial exercise period is set to expire on August 27, 2025.

Endocarditis, a heart infection caused by bacteria in the bloodstream, is experiencing growing incidence due to rising healthcare-associated infections, intravenous drug use, and aging populations with prosthetic valves. Advances in diagnostic imaging, AI-assisted echocardiography, and minimally invasive cardiac procedures are improving detection and patient outcomes. However, challenges like early detection difficulties and antimicrobial resistance persist. North America leads in the endocarditis market, with significant growth seen in the Asia-Pacific due to increased cardiovascular cases and healthcare investments. Key players like Pfizer and Teva Pharmaceutical are driving innovations in the sector.